Streetbeat News

Regulatory

VWAGY

Volkswagen is recalling 98,806 ID.4 electric SUVs in the U.S. due to a door handle malfunction that could cause doors to open unexpectedly. The recall affects models from 2021 to 2024. The company will inspect and replace door handles and update software at no cost to customers.

Portfolio Pulse from Anan Ashraf

September 10, 2024 | 11:09 am

ABBV

AbbVie has received Health Canada approval for CONSTELLA, a treatment for functional constipation in children aged 6 to 17. This marks the first approved prescription therapy for this condition in Canada, based on successful Phase 3 trial results.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:09 am

ITRM

Iterum Therapeutics announced that the FDA Antimicrobial Drugs Advisory Committee discussed their new drug application for oral sulopenem, a treatment for uncomplicated urinary tract infections in adult women. The FDA's decision is expected by October 25, 2024.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:06 am

AAPL

GOOGL

NVDA

ORCL

Nasdaq and S&P 500 futures dipped slightly as traders anticipate the presidential debate and upcoming inflation reports. Oracle's stock surged over 8% due to strong earnings and data center demand. Meanwhile, Apple and Alphabet faced setbacks from EU court rulings. Analysts note a shift from growth to value stocks amid weak economic data.

Portfolio Pulse from Shanthi Rexaline

September 10, 2024 | 11:05 am

SLRN

Acelyrin announced that it will present data from its Phase 1/2 clinical trial of Lonigutamab for Thyroid Eye Disease at the European Society of Ophthalmic Plastic and Reconstructive Surgery's annual meeting.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:03 am

ACON

Aclarion has completed the first Nociscan exams for patients in the LIFEHAB trial in Norway. The trial involves 202 patients with chronic low back pain and will compare outcomes between lumbar interbody fusion surgery and multidisciplinary rehabilitation.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 11:01 am

REGN

SNY

Sanofi and Regeneron presented results from their Phase 3 studies, BOREAS and NOTUS, showing that Dupixent significantly reduced exacerbations and improved lung function in patients with uncontrolled COPD and Type 2 inflammation. These findings were shared at the 2024 ERS International Congress.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 10:55 am

SILO

Silo Pharma has completed a pre-IND meeting with the FDA for SPC-15, an intranasal treatment for PTSD and stress-induced anxiety. The meeting focused on aligning with the FDA on the 505(b)(2) regulatory pathway, which could expedite approval and reduce costs.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 10:36 am

GOOG

GOOGL

Google, a subsidiary of Alphabet Inc., emphasized the importance of empowering users with fact-check tools amid the rising use of AI at the Global AI Summit. Google's reverse image search tool and the new SynthID technology are part of efforts to help users identify AI-generated content. The need for such tools is underscored by the misuse of AI in creating deepfakes and spreading disinformation.

Portfolio Pulse from Rounak Jain

September 10, 2024 | 10:35 am

GOOGL

IYF

PLTR

XOM

On CNBC's 'Final Trades,' experts discussed various stocks. iShares U.S. Financials ETF was highlighted by Shannon Saccocia. Exxon Mobil withdrew from a potential acquisition in Namibia. Alphabet faces scrutiny from the UK's CMA over ad tech practices. Palantir Technologies was added to the S&P 500, boosting its stock price.

Portfolio Pulse from Avi Kapoor

September 10, 2024 | 10:33 am